Literature DB >> 17595376

Neonatal long QT syndrome due to a de novo dominant negative hERG mutation.

Theresa A Beery1, Kerry A Shooner, D Woodrow Benson.   

Abstract

A 4-day-old girl with ventricular tachyarrhythmias, sinus bradycardia, and 2:1 atrioventricular block had prolongation of the QT interval. She was symptomatic with arching, gasping, and cyanosis presumably due to a life-threatening ventricular tachyarrhythmia such as torsades de pointes. Molecular genetic studies indicated a heterozygous, de novo, dominant negative mutation in hERG, a gene that encodes a protein in a potassium ion channel. The parents do not have the mutation. The patient's clinical scenario was produced by the convergence of 3 events: a de novo mutation occurred in hERG, the mutation was dominant negative, and the action of the mutation resulted in neonatal long QT syndrome. The child was treated aggressively and is doing well at age 6 years.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17595376

Source DB:  PubMed          Journal:  Am J Crit Care        ISSN: 1062-3264            Impact factor:   2.228


  4 in total

Review 1.  Fetal cardiac arrhythmia detection and in utero therapy.

Authors:  Janette F Strasburger; Ronald T Wakai
Journal:  Nat Rev Cardiol       Date:  2010-05       Impact factor: 32.419

2.  Genetic variants for long QT syndrome among infants and children from a statewide newborn hearing screening program cohort.

Authors:  Ruey-Kang R Chang; Yueh-Tze Lan; Michael J Silka; Hallie Morrow; Alan Kwong; Janna Smith-Lang; Robert Wallerstein; Henry J Lin
Journal:  J Pediatr       Date:  2013-12-31       Impact factor: 4.406

Review 3.  Long QT Syndrome and Sinus Bradycardia-A Mini Review.

Authors:  Ronald Wilders; Arie O Verkerk
Journal:  Front Cardiovasc Med       Date:  2018-08-03

4.  A missense mutation of ErbB2 produces a novel mouse model of stillbirth associated with a cardiac abnormality but lacking abnormalities of placental structure.

Authors:  Heba Shawer; Esther Aiyelaagbe; Christopher Clowes; Samantha C Lean; Yinhui Lu; Karl E Kadler; Alan Kerby; Mark R Dilworth; Kathryn E Hentges; Alexander E P Heazell
Journal:  PLoS One       Date:  2020-06-03       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.